C-Reactive Protein Testing Market Size, Share, and Growth Forecast 2026 - 2033

The global C-Reactive Protein testing market size is expected to be valued at US$ 2.9 billion in 2026 and projected to reach US$ 4.1 billion growing at a CAGR of 5.1% between 2026 and 2033. The C-Reactive Protein (CRP) Testing Market is experiencing steady growth, driven by the increasing prevalence of infectious diseases, cardiovascular disorders, autoimmune conditions, and chronic inflammatory diseases worldwide.

CRP testing is widely used to detect inflammation, monitor disease progression, and evaluate treatment response in both hospital and outpatient settings. Growing adoption of high-sensitivity CRP (hs-CRP) tests for cardiovascular risk assessment, rising demand for point-of-care diagnostics, and advancements in immunoassay technologies are supporting market expansion.

Drivers - Rising Global Burden of Infectious Diseases and Sepsis-Driven CRP Testing Demand

The escalating global burden of infectious diseases and sepsis represents a primary structural growth driver for the CRP testing market. According to the World Health Organization (WHO), sepsis affects approximately 49 million people annually and causes 11 million deaths per year, making rapid inflammatory biomarker measurement, including CRP, an essential component of emergency and critical care diagnostic protocols. The COVID-19 pandemic further amplified clinical awareness of CRP's utility: elevated CRP levels were strongly correlated with severe disease progression and intensive care admission risk, prompting widespread institutional adoption of CRP monitoring beyond traditional infectious disease workflows. The WHO's Global Action Plan on Antimicrobial Resistance (AMR) explicitly endorses CRP-guided antibiotic stewardship as a key intervention to reduce inappropriate antibiotic prescribing, creating sustained policy-driven demand for CRP testing in primary care and community health settings globally.

Growing Clinical Adoption of hs-CRP Testing in Cardiovascular Risk Stratification

High-sensitivity C-Reactive Protein (hs-CRP) testing has emerged as a validated and clinically actionable tool for cardiovascular risk stratification, creating growing and durable diagnostic demand independent of infectious disease applications. The American Heart Association (AHA) and Centers for Disease Control and Prevention (CDC) jointly endorse hs-CRP measurement as a complementary cardiac risk assessment biomarker, particularly for patients with intermediate cardiovascular risk profiles who may benefit from statin therapy initiation.

The landmark JUPITER clinical trial published in the New England Journal of Medicine demonstrated that rosuvastatin significantly reduced cardiovascular events in patients with elevated hs-CRP but normal LDL cholesterol levels, establishing hs-CRP as a clinically actionable marker beyond lipid panels. The WHO reports that cardiovascular diseases account for approximately 17.9 million deaths annually, representing 32% of all global mortality, sustaining growing physician adoption of hs-CRP panels as part of comprehensive preventive cardiology protocols globally.

Restraints - Limited Diagnostic Specificity of CRP as a Standalone Inflammatory Biomarker

CRP's principal clinical limitation is its non-specificity as an acute phase reactant that elevates across bacterial infections, viral illnesses, autoimmune flares, trauma, and malignancy, restricting its utility as a standalone diagnostic tool and constraining premium test pricing strategies. Clinicians frequently require CRP in combination with procalcitonin, interleukin-6, and white blood cell differentials to achieve meaningful bacterial-versus-viral diagnostic differentiation, a multi-test requirement that increases per-patient workup cost and may reduce CRP-specific reimbursement in cost-containment environments. This non-specificity concern is particularly pronounced in sepsis management, where more targeted biomarkers are gaining clinical preference over CRP alone, gradually eroding its exclusive positioning in acute infection diagnostic pathways.

Inconsistent Reimbursement Policies and Pricing Pressure in Emerging Markets

Heterogeneous and restrictive reimbursement frameworks for CRP testing, particularly for hs-CRP cardiovascular risk assessments across major public payer systems, represent a persistent structural growth restraint. In the United States, Centers for Medicare & Medicaid Services (CMS) reimbursement for hs-CRP under the Medicare Physician Fee Schedule (MPFS) remains confined to specific high-risk cardiovascular patient populations, limiting utilization in broader preventive care contexts. Across emerging markets in Asia and Latin America, low public health insurance reimbursement rates for laboratory diagnostics and high out-of-pocket cost burdens constrain adoption of premium automated CRP analyzer platforms, pushing demand toward lower-margin lateral flow and rapid POC assay formats that limit revenue growth for instrument and high-complexity reagent manufacturers.

Opportunities - Rapid Growth of Point-of-Care CRP Testing in Antibiotic Stewardship and Primary Care

Point-of-care (POC) CRP testing represents the fastest-growing segment in the market, driven by an accelerating convergence of clinical evidence, regulatory endorsement, and antibiotic stewardship policy that collectively mandate rapid near-patient inflammatory assessment in primary care, emergency medicine, and community health settings. The WHO's Global Action Plan on AMR explicitly endorses POC CRP testing as an antibiotic stewardship tool in primary care, where rapid turnaround time is operationally essential.

Robust clinical evidence from European primary care networks demonstrates that POC CRP-guided antibiotic prescribing protocols reduce unnecessary antibiotic prescriptions by up to 30-40%, creating a compelling health economic case for institutional procurement. Companies including Boditech Med Inc., ACON Laboratories, Inc., and Siemens Healthineers AG have all expanded their POC CRP product portfolios with quantitative, cartridge-based systems, validating the segment's commercial trajectory. Vendors offering affordable, user-friendly single-use POC CRP platforms with connectivity to electronic health record (EHR) systems are optimally positioned to capture demand from GP practices, urgent care clinics, and community pharmacies globally.

Cardiovascular Disease Applications Emerging as the Fastest Growing Disease Area

The cardiovascular diseases application segment for CRP testing is the fastest growing disease area, powered by escalating global CVD incidence and the progressive integration of hs-CRP into clinical cardiovascular risk stratification guidelines. The WHO reports that cardiovascular diseases cause approximately 17.9 million deaths annually, and the growing population of intermediate-CVD-risk individuals for whom hs-CRP provides incremental risk information beyond traditional lipid panels is expanding the addressable clinical testing population.

The American College of Cardiology/AHA 2019 primary prevention guidelines identify elevated hs-CRP (≥2 mg/L) as a risk-enhancing factor warranting therapeutic consideration in statin decision-making for borderline-risk patients. F. Hoffmann-La Roche Ltd. and Abbott Laboratories have developed next-generation hs-CRP analyzer platforms optimized for high-throughput cardiovascular diagnostic workflows, while clinical laboratories are increasingly embedding hs-CRP as a reflexive add-on within comprehensive cardiovascular biomarker panels, creating a growing and high-value revenue stream for diagnostic manufacturers.

Product Type Insights

Reagents and kits command approximately 65% of the global CRP testing market in 2026, a dominant position driven by the recurring, high-volume consumable nature of diagnostic test reagent procurement and the extensive installed base of automated clinical chemistry analyzers requiring continuous reagent replenishment. Unlike instruments, which represent periodic capital expenditures with multi-year replacement cycles, CRP reagents and assay kits generate predictable, procedure-volume-linked revenue streams that compound with testing volume growth.

The high global volume of annual CRP test procedures encompassing infectious disease monitoring, post-surgical inflammation surveillance, and cardiovascular risk screening sustains consistent reagent consumption across hospital and reference laboratory settings. Leading manufacturers including F. Hoffmann-La Roche Ltd., Abbott Laboratories, and Siemens Healthineers AG supply closed-system reagent cartridges and immunoturbidimetric kits calibrated for their proprietary analyzer platforms, reinforcing segment dominance through platform lock-in and long-term supply agreement structures.

Testing Type Insights

Laboratory testing accounts for 62% of the CRP testing market by testing modality in 2026, driven by the extensive installed base of automated immunoturbidimetric and immunonephelometric analyzers in hospital clinical chemistry laboratories and independent diagnostic facilities globally. High-volume clinical laboratories process large numbers of CRP test orders daily through automated platforms, benefiting from superior analytical precision, extended dynamic range, and seamless LIS workflow integration that point-of-care alternatives currently cannot replicate for complex or high-acuity clinical applications. The Clinical and Laboratory Standards Institute (CLSI) endorses laboratory-based immunoturbidimetry as the reference standard methodology for CRP quantification, sustaining institutional procurement preference in tertiary and secondary care settings. However, the segment's relative growth rate is being increasingly challenged by accelerating POC CRP testing adoption in primary care, antibiotic stewardship, and community health worker applications globally.

Disease Area Insights

Infectious diseases represent the leading disease application segment in the CRP testing market, accounting for approximately 41% of global revenue in 2025, a position that reflects CRP's foundational clinical role as a first-line inflammatory biomarker for infection detection, severity stratification, and treatment response monitoring. According to the World Health Organization (WHO), lower respiratory tract infections and sepsis collectively represent among the most prevalent indications for emergency and inpatient laboratory diagnostic testing globally. CRP-guided antibiotic stewardship protocols endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) are progressively institutionalizing regular CRP measurement within hospital infection management and primary care pathways. The integration of CRP into automated sepsis alert algorithms and clinical decision support tools deployed within hospital information systems by leading providers is further reinforcing and growing test volume in this dominant application segment.

End-user Insights

Hospitals account for 48% of the CRP testing market by end user in 2026, driven by the high volume of acute care, emergency, and critical care patients requiring inflammatory biomarker assessment for infection diagnosis, sepsis monitoring, autoimmune disease evaluation, and post-operative complication surveillance. The concentration of advanced automated clinical chemistry analyzers, including high-throughput platforms from F. Hoffmann-La Roche Ltd., Abbott Laboratories, and Danaher Corporation (Beckman Colter) within hospital laboratory settings enables large-scale, high-precision CRP measurement as part of routine admission and monitoring protocols.

According to the WHO, hospitals remain the primary institutional setting globally for acute infectious disease diagnosis and management, reinforcing their dominant share of CRP test ordering. Academic medical centers and tertiary care hospitals also serve as primary early adopters of hs-CRP cardiovascular risk assessment protocols, sustaining premium instrument and reagent procurement within the hospital channel.

North America C-Reactive Protein Testing Market Trends and Insights

North America leads the global CRP testing market with a 38% revenue share in 2026, supported by well-developed clinical laboratory infrastructure, strong AHA/ACC and CDC clinical guideline endorsement of hs-CRP in cardiovascular risk assessment, and high per-capita healthcare expenditure sustaining consistent laboratory test utilization. The region benefits from broad insurance reimbursement for CRP testing in acute infection and sepsis management, driving high testing volumes across hospital laboratories, outpatient diagnostic centers, and growing POC CRP adoption in primary care antibiotic stewardship programs.

U.S. C-Reactive Protein Testing Market Size

The United States accounts for 85% of North American CRP testing revenue in 2026. AHA and CDC joint endorsement of hs-CRP for cardiac risk stratification, combined with CMS reimbursement coverage for CRP in infectious disease diagnostic workups, sustains high testing volumes across the country's dense clinical laboratory network comprising over 260,000 CLIA-certified laboratory sites. Rising cardiovascular disease screening initiatives and expanding sepsis alert protocols in U.S. hospitals are expected to drive continued testing volume growth through the forecast period.

Europe C-Reactive Protein Testing Market Trends and Insights

Europe represents the second-largest regional market for CRP testing, underpinned by well-funded public healthcare systems, strong ESC and ESCMID clinical guideline endorsement of CRP in cardiovascular and infectious disease management, and national antibiotic stewardship programs mandating CRP testing in primary care respiratory infection evaluation. Germany, the U.K., and France are the primary revenue contributors, collectively accounting for over 50% of European testing volumes through hospital and community laboratory networks.

Germany C-Reactive Protein Testing Market Size

Germany holds approximately 22% of the European CRP testing market in 2026, driven by a dense hospital and diagnostic laboratory network, high participation in antibiotic stewardship programs, and strong institutional adoption of automated CRP analyzers. The presence of Siemens Healthineers AG, headquartered in Munich, contributes to strong domestic technology adoption and clinical research infrastructure supporting advanced CRP and hs-CRP diagnostic applications across cardiology and internal medicine departments.

U.K. C-Reactive Protein Testing Market Size

The United Kingdom contributes 16% of European CRP testing market revenue in 2026, supported by NHS England protocols mandating CRP measurement within pneumonia severity scoring systems (including the CRB-65 score) and sepsis management pathways. Expanding NHS Primary Care Networks are increasingly deploying POC CRP testing platforms to guide antibiotic prescriptions for respiratory tract infections across GP practices, driving strong adoption growth in the POC segment.

France C-Reactive Protein Testing Market Size

France accounts for 14% of the European CRP testing market in 2026. National antibiotic stewardship guidelines issued by the Société de Pathologie Infectieuse de Langue Française (SPILF) and GPIP recommend POC CRP testing in primary care evaluation of respiratory tract infections, sustaining consistent demand for both laboratory-based and point-of-care CRP testing platforms across hospital outpatient departments and ambulatory care networks.

Asia Pacific C-Reactive Protein Testing Market Trends and Insights

Asia Pacific is the fast-growing regional market for CRP testing, driven by China's expanding hospital network and government healthcare reform programs under the Healthy China 2030 initiative, high infectious disease burden across South and Southeast Asia, and growing cardiovascular disease prevalence supporting hs-CRP adoption. Rapid expansion of organized private diagnostic laboratory chains in India and Southeast Asia is accelerating CRP testing volume growth, while Japan and South Korea maintain mature, high-precision laboratory CRP markets driven by strong autoimmune and cardiovascular disease diagnostic protocols.

India C-Reactive Protein Testing Market Size

India holds 11% of the Asia Pacific CRP testing market in 2026, driven by a high infectious disease burden including tuberculosis, dengue, and bacterial pneumonia and rapid expansion of organized diagnostic laboratory chains including Dr. Lal PathLabs and Metropolis Healthcare, which are progressively expanding CRP test menu offerings across urban, semi-urban, and tier-2 city markets. Growing government investment in infection diagnostics under the National Health Mission (NHM) further supports market expansion.

The C-Reactive Protein (CRP) Testing Market is highly competitive, driven by continuous advancements in diagnostic technologies and the growing demand for rapid inflammation and infection testing. Leading companies such as Roche, Abbott, Siemens Healthineers, Danaher, Thermo Fisher Scientific, and bioMérieux compete through extensive product portfolios, high-sensitivity CRP (hs-CRP) assays, and integrated laboratory automation solutions. Market participants are strengthening their positions through product launches, strategic partnerships, acquisitions, and geographic expansion, while increasing investments in point-of-care testing improve accessibility and turnaround times.

Key Developments

• In May 2024, Radiometer launched the AQT90 FLEX immunoassay analyzer with CRP testing, delivering results in under 13 minutes. Its closed-tube design minimized exposure and supported both whole blood and plasma, ideal for emergency and bedside use.
• In January 2024, Siemens HealthCare Diagnostics Inc. received FDA 510(k) clearance for its Atellica CH High Sensitivity CRP 2 (hCRP2) assay, enabling quantitative CRP testing in serum and plasma using the Atellica CH Analyzer.